产品
编 号：F756810
分子式：C27H35N3O5S2
分子量：545.71
分子式：C27H35N3O5S2
分子量：545.71
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2914878-00-3
产品详情
生物活性：
KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-dependent ATPase activity.
体内研究：
KIF18A-IN-7 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。Animal Model:SCID Beige mice, HCC15 tumor model
Dosage:10, 30 and 60 mg/kg
Administration:PO, twice a day for 1 month
Result:Inhibited tumor growth by 30±15%, 72±6% and 82±9% at 10, 30 and 60 mg/kg, respectively.
Animal Model:Balb/C nude mice, OVCAR3 tumor model
Dosage:10, 30 and 60 mg/kg
Administration:PO, once a day for 1 month
Result:Inhibited tumor growth by 24±26%, 72±17% and 82±10% at 10, 30 and 60 mg/kg, respectively.
体外研究：
KIF18A-IN-7 (Compound 22; 7 days) 抑制 JIMT-1、NIH-OVCAR3 和 HCC-15 细胞活力，IC50 分别为 0.0078、0.0097 和 0.011 μM。
KIF18A-IN-7 (Compound 22) is an orally active KIF18A inhibitor with an IC50 of 9.4 nM against KIF18A microtubule-dependent ATPase activity.
体内研究：
KIF18A-IN-7 (Compound 22; 10-60 mg/kg; p.o.; twice or once a day for 1 month) 抑制小鼠 HCC15 和 OVCAR3 肿瘤生长。Animal Model:SCID Beige mice, HCC15 tumor model
Dosage:10, 30 and 60 mg/kg
Administration:PO, twice a day for 1 month
Result:Inhibited tumor growth by 30±15%, 72±6% and 82±9% at 10, 30 and 60 mg/kg, respectively.
Animal Model:Balb/C nude mice, OVCAR3 tumor model
Dosage:10, 30 and 60 mg/kg
Administration:PO, once a day for 1 month
Result:Inhibited tumor growth by 24±26%, 72±17% and 82±10% at 10, 30 and 60 mg/kg, respectively.
体外研究：
KIF18A-IN-7 (Compound 22; 7 days) 抑制 JIMT-1、NIH-OVCAR3 和 HCC-15 细胞活力，IC50 分别为 0.0078、0.0097 和 0.011 μM。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备